BioNTech reported Q3 revenue of €1.3 billion, down from €1.5 billion a year earlier due to weaker COVID-19 vaccine demand, but raised its 2026 revenue outlook to €1.7 billion–€1.9 billion. The company ended the quarter with €16.2 billion in cash and investments.
